Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Depreciation & Amortization (CF) (2016 - 2025)

Agios Pharmaceuticals' Depreciation & Amortization (CF) history spans 14 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 7.39% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $5.2 million, down 8.42%, while the annual FY2025 figure was $5.2 million, 8.42% down from the prior year.
  • Depreciation & Amortization (CF) reached $1.3 million in Q4 2025 per AGIO's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.5 million in Q1 2021 to a low of $1.3 million in Q2 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $1.8 million, with a median of $1.7 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): fell 27.76% in 2023, then rose 2.16% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.2 million in 2021, then decreased by 17.62% to $1.8 million in 2022, then dropped by 22.66% to $1.4 million in 2023, then fell by 2.57% to $1.4 million in 2024, then dropped by 7.39% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Depreciation & Amortization (CF) are $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $1.3 million (Q2 2025).